Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone. Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with K_i of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC₅₀ of 680 nM^[1]. IC50 & Target: Ki: 1.2 μM (PPARγ LBD); EC: 680 nM (PPARγ LBD) (Leriglitazone)^[1]